A study in the Journal of the American Medical Association indicates that ubrogepant demonstrated greater rates of pain and symptom relief from migraine compared with a placebo. More than 20% of participants in a large-scale clinical trial reported being pain-free within 2 hours and more than 34% were relieved of the most severe symptoms associated with migraines when administered the drug, compared with 14% and 27%, respectively, from the placebo. These symptoms include light and noise sensitivity. Richard B. Lipton, MD, director of the Montefiore Headache Center in New York, who led the study, observes: “Migraine is the second leading cause of disability, and we need new acute treatments that are efficacious, safe, and tolerable.” Lipton is a consultant for Allergan, the pharmaceutical company that sponsored the trial. Ubrogepant is currently pending approval by the FDA. The drug targets a protein called calcitonin gene-related peptide, which is involved in the transmission of pain.
Subscribe To Our Weekly Newsletter
acute migraine adolescents Alzheimer's disease Alzheimers anxiety back pain blood pressure botox brain caffeine children chronic migraine chronic pain cluster headache concussion concussions dementia depression diet exercise fibromyalgia Headache headache blog headaches health heart disease meditation men migraine migraine headache migraine headaches migraines migraine triggers migraine with aura pain physical activity sleep stress stroke triggers triptans vitamin D walking women yoga